XNAS · EDIT
-1.41% · -$0.0400 · Vol Not reported
Pre-market · updated 04:01:26 ET
Editas Medicine, Inc. Common Stock

Editas Medicine, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$2.80
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
EDIT
Editas Medicine, Inc. Common Stock
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for EDIT until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is EDIT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading EDIT catalysts
About Editas Medicine, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2016
Employees
87
Country
US

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.84
Last session
Day high
$2.84
Last session
Day low
$2.84
Last session
Previous close
$2.84
52W high
$4.15
-32.53% from high
52W low
$1.67
46% of range
Market cap
$433.1M
EPS
$-1.3200
Beta
1.76
Shares out
153.6M
Avg volume
1.8M
VWAP
$2.84
Last session
Price history computed in-house
1W
-5.08%
1M
-6.04%
3M
+7.69%
1Y
+2.56%
YTD
+36.59%
SMA 50 $2.87 · below
SMA 200 $2.59 · above
52W position 46%

EDIT overview

Veridion Score
Not reported
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around EDIT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading EDIT Form 4 filings
Public disclosures

Congress activity in EDIT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for EDIT in the cached public ledger.

Federal contracts

EDIT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EDIT in this window.
Lobbying spend

EDIT lobbying filings, year to date.

Registered lobbying filings matched to Editas Medicine, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EDIT in this window.
Loading news for EDIT
Analyst ratings
Sovereign unlock shows live analyst consensus for EDIT.
Options
Sovereign unlock shows live options positioning for EDIT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.